Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

被引：0
|
作者：
Yaman, Samet [1 ]
Bilgin, Burak [2 ]
Sendur, Mehmet A. N. [2 ]
Hizal, Mutlu [2 ]
Akinci, Muhammed Bulent [2 ]
Yalcin, Bulent [2 ]
机构：
[1] Ankara Yildirim Beyazit Univ, Dept Internal Med, Ankara, Turkey
[2] Ankara Yildirim Beyazit Univ, Dept Med Oncol, Ankara, Turkey
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 09期
关键词：
immunotherapy; renal cell carcinoma; tyrosine kinase inhibitors; INTERFERON-ALPHA; SUNITINIB; INTERMEDIATE; CABOZANTINIB; PAZOPANIB; SURVIVAL; THERAPY; POOR; RISK;
D O I：
10.2217/fon-2018-0503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：925 / 927
页数：3
相关论文
共 50 条
  • [1] Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?
    Mickisch, G.
    Peters, I.
    Gruellich, C.
    Mudra, T.
    Doehn, C.
    UROLOGE, 2020, 59 (12): : 1504 - 1511
  • [2] Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
    Roviello, Giandomenico
    Buti, Sebastiano
    Cattrini, Carlo
    Mennitto, Alessia
    Messina, Carlo
    Airoldi, Chiara
    Vannini, Gianmarco
    Bersanelli, Melissa
    THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [3] Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
    Poprach, Alexandr
    Rumanova, Kristina
    Lakomy, Radek
    Chloupkova, Renata
    Stanik, Michal
    Pokrivcak, Tomas
    Kiss, Igor
    Slaby, Ondrej
    Studentova, Hana
    Melichar, Bohuslav
    Juracek, Jaroslav
    Fiala, Ondrej
    Kopecky, Jindrich
    Kopeckova, Katerina
    Zemanova, Milada
    Buchler, Tomas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (04) : 294.e1 - 294.e8
  • [4] First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience
    Rudresha, A. H.
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Babu, Govind K.
    Lokanatha, D.
    Jacob, Linu Abraham
    Babu, Suresh M. C.
    Lokesh, K. N.
    Rajeev, L. K.
    INDIAN JOURNAL OF CANCER, 2017, 54 (04) : 626 - 630
  • [5] Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma
    Arter, Zhaohui
    Benjamin, David Joseph
    Cao, Yen
    Forsyth, Michael
    Thirumaran, Ranjit
    Farias, Jorge
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma
    Hahn, Andrew W.
    Froerer, Camryn
    VanAlstine, Sidney
    Rathi, Nityam
    Bailey, Erin B.
    Stenehjem, David D.
    Agarwal, Neeraj
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : 365 - 368
  • [7] Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.
    Hess, G. P.
    Chen, C.
    Liu, Z.
    Gesme, D. H.
    Agarwala, S. S.
    Hill, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [9] Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma
    Korkmaz, Mustafa
    Erylmaz, Melek Karakurt
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (06): : 653 - 658
  • [10] Optimal sequential therapy using tyrosine kinase inhibitors as the first-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study
    Jo, Jung Ki
    Kang, Minyong
    Chung, Jinsoo
    Kwak, Cheol
    Hong, Sung-Hoo
    Song, Cheryn
    Park, Jae Young
    Jeong, Chang Wook
    Choi, Seok Hwan
    Kim, Sung Han
    Hwang, Eu Chang
    Lee, Chan Ho
    Lee, Hakmin
    ASIAN JOURNAL OF UROLOGY, 2024, 11 (03) : 450 - 459
12345